Citations

Clear

4847 citation(s) found for "Yu, Eric".

IL-23 amplifies the epithelial-mesenchymal transition of mechanically conditioned alveolar epithelial cells in rheumatoid arthritis-associated interstitial lung disease through mTOR/S6 signaling
Zhang, Chujie , Wang, Shaohua , Lau, Jessica, Roden, Anja C. , Matteson, Eric L. , Tschumperlin, Daniel J. , Vassallo, Robert , Tschumperlin, Daniel J , Vassallo, Robert , Sun, Jie , Luo, Fengming

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | September 29, 2021 | Volume: 321 | Issue: 6 | Pages: L1006-L1022

10.1152/ajplung.00292.2021 | PMID 34585990 Get It

Epithelial-mesenchymal transition (EMT) creates an environment facilitating fibrosis following alveolar epithelial cell injury. IL-23 has important roles in chronic autoimmune conditions like rheumatoid arthritis (RA), but its role in the interstitial lung disease that affects patients with RA is unclear. This study aimed to determine the profibrogenic role of IL-23 on somatic alveolar type I (ATI) epithelial cells. Primary ATI cells were isolated from rats and cultured on plastic dishes for 1–3 wk. After prolonged culture (≥14 days) on rigid culture dishes, primary ATI cells gradually acquired a mesenchymal phenotype, identified by decreased expression of caveolin-1, and reorganization of F-actin cytoskeleton, indicating the initiation of EMT by matrix stiffness. To determine how IL-23 promotes EMT in vitro, transitioning ATI cells, cultured on a stiff substrate for ≥14 days were stimulated with IL-23. The EMT phenotype was significantly enhanced by IL-23, which upregulated α-smooth muscle actin (α-SMA), collagen I/III protein, and decreased caveolin-1. Furthermore, IL-23 significantly promoted cell invasion, as well as apoptotic resistance on transitioning ATI cells. Mechanistically, IL-23-induced EMT was mammalian target of rapamycin/ribosomal protein S6 (mTOR/S6) signaling dependent and reversible by rapamycin. Transcriptional sequencing analysis of human lung fibrosis biopsy tissue revealed key roles for IL-23 in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). This result was further validated by significantly upregulated IL-23 expression at the mRNA level in RA-ILD lung sections. Notably, transitioning ATI epithelial cells were abundantly detected in RA-ILD tissue. Taken together, these data support a role for IL-23 in the pathogenesis of RA lung fibrosis by promoting EMT in alveolar epithelial cells through mTOR/S6 signaling.
Emerging concepts in endoscopic skull base surgery training
Rabinowitz, Mindy, Patel, Zara M. , McKinney, Kibwei A. , Signore, Anthony G. Del, Ebert, Charles S. , Thorp, Brian D. , Choby, Garret , Patel, Zara , Wang, Eric W , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | September 27, 2021 | Volume: 11 | Issue: 12 | Pages: 1611-1616

10.1002/alr.22895 | PMID 34569168 Get It

Does reduction of the Meyerding grade correlate with outcomes in patients undergoing decompression and fusion for grade I degenerative lumbar spondylolisthesis?
Chan, Andrew K. , Mummaneni, Praveen V. , Burke, John F. , Mayer, Rory , Bisson, Erica F. , Rivera, Joshua, Pennicooke, Brenton , Fu, Kai-Ming, Park, Paul , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Wang, Michael Y. , Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Haid, Regis W., Chou, Dean , Alvi, Mohammed A, Alvi, Mohammed Ali , Guan, Jian

Mayo Clinic

Journal of Neurosurgery: Spine | September 25, 2021 | Volume: 36 | Issue: 2 | Pages: 177-184

10.3171/2021.3.spine202059 | PMID 34534963 Get It

OBJECTIVE Reduction of Meyerding grade is often performed during fusion for spondylolisthesis. Although radiographic appearance may improve, correlation with patient-reported outcomes (PROs) is rarely reported. In this study, the authors’ aim was to assess the impact of spondylolisthesis reduction on 24-month PRO measures after decompression and fusion surgery for Meyerding grade I degenerative lumbar spondylolisthesis. METHODS The Quality Outcomes Database (QOD) was queried for patients undergoing posterior lumbar fusion for spondylolisthesis with a minimum 24-month follow-up, and quantitative correlation between Meyerding slippage reduction and PROs was performed. Baseline and 24-month PROs, including the Oswestry Disability Index (ODI), EQ-5D, Numeric Rating Scale (NRS)–back pain (NRS-BP), NRS-leg pain (NRS-LP), and satisfaction (North American Spine Society patient satisfaction questionnaire) scores were noted. Multivariable regression models were fitted for 24-month PROs and complications after adjusting for an array of preoperative and surgical variables. Data were analyzed for magnitude of slippage reduction and correlated with PROs. Patients were divided into two groups: < 3 mm reduction and ≥ 3 mm reduction. RESULTS Of 608 patients from 12 participating sites, 206 patients with complete data were identified in the QOD and included in this study. Baseline patient demographics, comorbidities, and clinical characteristics were similarly distributed between the cohorts except for depression, listhesis magnitude, and the proportion with dynamic listhesis (which were accounted for in the multivariable analysis). One hundred four (50.5%) patients underwent lumbar decompression and fusion with slippage reduction ≥ 3 mm (mean 5.19, range 3 to 11), and 102 (49.5%) patients underwent lumbar decompression and fusion with slippage reduction < 3 mm (mean 0.41, range 2 to −2). Patients in both groups (slippage reduction ≥ 3 mm, and slippage reduction < 3 mm) reported significant improvement in all primary patient reported outcomes (all p < 0.001). There was no significant difference with regard to the PROs between patients with or without intraoperative reduction of listhesis on univariate and multivariable analyses (ODI, EQ-5D, NRS-BP, NRS-LP, or satisfaction). There was no significant difference in complications between cohorts. CONCLUSIONS Significant improvement was found in terms of all PROs in patients undergoing decompression and fusion for lumbar spondylolisthesis. There was no correlation with clinical outcomes and magnitude of Meyerding slippage reduction.
Trends in Diagnosis and Treatment of Metastatic Cancer in the United States
Lehrer, Eric J. , Stoltzfus, Kelsey C. , Walter, Vonn , Louie, Alexander V. , Walter, Vonn , Jones, Brianna M. , Gusani, Niraj J. , Wang, Ming , Trifiletti, Daniel M. , Siva, Shankar , Zaorsky, Nicholas G.

Mayo Clinic

American Journal of Clinical Oncology | September 24, 2021 | Volume: 44 | Issue: 11 | Pages: 572-579

10.1097/coc.0000000000000866 | PMID 34560720 Get It

Objectives: Metastatic cancer has historically been considered fatal; however, there is a paucity of evidence characterizing the epidemiology of incidence, treatment, and outcomes in these patients. Materials and Methods: Incidence rates, annual percent change (APC), descriptive epidemiological statistics, and odds ratios for survival were calculated using registry data from the Surveillance, Epidemiology, and End Results (SEER) and the National Cancer Database (NCDB), 1998 to 2015. Results: There were a total of 1,055,860 patients with metastatic cancer. The most frequent primary cancers were lung (42.6%), colorectal (9.5%), and ovarian (5.5%). Metastatic lung and colorectal cancer incidence decreased, APC: −1.57 (P<0.001) and APC: −1.48 (P<0.001), respectively; metastatic pancreatic cancer incidence increased, APC: 0.62 (P=0.001). The use of local therapies decreased for almost all sites, and the use of systemic therapies increased across multiple sites: single-agent chemotherapy in kidney (2.54% increase/year), female breast (1.14% increase/year), and prostate cancer (1.08% increase/year); multiagent chemotherapy, most notably in pancreas (2.23% increase/year), uterus (1.81% increase/year), and colorectal cancer (1.54% increase/year). Increased utilization of immunotherapy was observed across the majority of sites, most notably in melanoma (2.14% increase/year). Patients diagnosed from 2006 to 2010 had 17.4% higher odds of surviving at least 60 months compared with 1998 to 2002. Conclusions: In this study, metastatic disease has been shown to have unique epidemiological patterns, and survival has improved. Continued research on metastatic disease is important in understanding and addressing the distinct health concerns of this population.
Understanding diagnostic processes in emergency departments: a mixed methods case study protocol
Daniel, Michelle , Chandanabhumma, P. Paul , Fetters, Michael D. , Canvasser, Andrew B, Singh, Hardeep , Mahajan, Prashant , Pasupathy, Kalyan, Singh, Hardeep , Park, Sun Young , Seifert, Colleen M. , Wilson, Eric A. , Pasupathy, Kalyan S.

Mayo Clinic

BMJ Open | September 24, 2021 | Volume: 11 | Issue: 9 | Pages: e044194

10.1136/bmjopen-2020-044194 | PMID 34561251 Get It

Introduction Diagnostic processes in the emergency department (ED) involve multiple interactions among individuals who interface with information systems to access and record information. A better understanding of diagnostic processes is needed to mitigate errors. This paper describes a study protocol to map diagnostic processes in the ED as a foundation for developing future error mitigation strategies. Methods and analysis This study of an adult and a paediatric academic ED uses a prospective mixed methods case study design informed by an ED-specific diagnostic decision-making model (the modified ED-National Academies of Sciences, Engineering and Medicine (NASEM) model) and two cognitive theories (dual process theory and distributed cognition). Data sources include audio recordings of patient and care team interactions, electronic health record data, observer field notes and stakeholder interviews. Multiple qualitative analysis methods will be used to explore diagnostic processes in situ, including systems information flow, human–human and human–system interactions and contextual factors influencing cognition. The study has three parts. Part 1 involves prospective field observations of patients with undifferentiated symptoms at high risk for diagnostic error, where each patient is followed throughout the entire care delivery process. Part 2 involves observing individual care team providers over a 4-hour window to capture their diagnostic workflow, team coordination and communication across multiple patients. Part 3 uses interviews with key stakeholders to understand different perspectives on the diagnostic process, as well as perceived strengths and vulnerabilities, in order to enrich the ED-NASEM diagnostic model. Ethics and dissemination The University of Michigan Institutional Review Board approved this study, HUM00156261. This foundational work will help identify strengths and vulnerabilities in diagnostic processes. Further, it will inform the future development and testing of patient, provider and systems-level interventions for mitigating error and improving patient safety in these and other EDs. The work will be disseminated through journal publications and presentations at national and international meetings.
Enhancing public health and safety by diagnosing and treating obstructive sleep apnea in the transportation industry: an American Academy of Sleep Medicine position statement
Das, Aneesa M., Chang, Judy L., Berneking, Michael , Hartenbaum, Natalie P., Rosekind, Mark R., Ramar, Kannan , Malhotra, Raman K. , Carden, Kelly A., Abbasi-Feinberg, Fariha, Aurora, R. Nisha , Olson, Eric J. , Rosen, Carol L. , Rowley, James A. , Shelgikar, Anita V., Trotti, Lynn Marie , Gurubhagavatula, Indira , Trotti, Lynn Marie , Martin, Jennifer L. , Kapur, Vishesh K.

Mayo Clinic

Journal of Clinical Sleep Medicine | September 21, 2021 | Volume: 18 | Issue: 10 | Pages: 2467-2470

10.5664/jcsm.9670 | PMID 34534065 Get It

Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee
Fung, Maxwell A. , Vidal, Claudia I. , Armbrecht, Eric A., Andea, Aleodor A. , Cassarino, David S. , Comfere, Nneka I. , Emanuel, Patrick O. , Ferringer, Tammie , Kim, Jinah , Lauer, Scott , Linos, Konstantinos , Missall, Tricia A. , Sundram, Uma , Panel, Rating, Calame, Antoanella , Duncan, Lyn M. , Elston, Dirk M. , Hosler, Gregory A. , Hurley, Yadira, Messina, Jane L. , Myles, Jonathan P. , Prieto, Víctor G. , Reddy, Vijaya , Schaffer, András , Subtil, Antonio , Fung, Maxwell A , Vidal, Claudia I , Cassarino, David S , Comfere, Nneka , Emanuel, Patrick O , Kim, Jinah , Linos, Konstantinos , Missall, Tricia A , Motaparthi, Kiran , Patel, Rajiv M , Sundram, Uma , Hosler, Gregory A , Hurley, Maria Yadira , Messina, Jane , Plaza, Jose Antonio , Prieto, Victor G , Subtil, Antonio , Hristov, Alexandra C. , Novoa, Roberto A. , Patel, Rajiv M. , Shalin, Sara C. , Panel, Rating, Bennett, Daniel D , Lazar, Alexander J. , Lowe, Lori , Myles, Jonathan

Mayo Clinic

Journal of Cutaneous Pathology | September 18, 2021 | Volume: 49 | Issue: 3 | Pages: 231-245

10.1111/cup.14135 | PMID 34536035 Get It

AbstractBackgroundAppropriate use criteria (AUC) provide patient‐centered physician guidance in test selection. An initial set of AUC was reported by the American Society of Dermatopathology (ASDP) in 2018. AUC reflect evidence collected at single timepoints and may be affected by evolving evidence and experience. The objective of this study was to update and expand AUC for selected tests.MethodsRAND/UCLA (RAND Corporation [Santa Monica, CA]/University of California Los Angeles) methodology used includes the following: (a) literature review; (b) review of previously rated tests and previously employed clinical scenarios; (c) selection of previously rated tests for new ratings; (d) development of new clinical scenarios; (e) selection of additional tests; (f) three rating rounds with feedback and group discussion after rounds 1 and 2.ResultsFor 220 clinical scenarios comprising lymphoproliferative (light chain clonality), melanocytic (comparative genomic hybridization, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, telomerase reverse transcriptase promoter), vascular disorders (MYC), and inflammatory dermatoses (periodic acid‐Schiff, Gömöri methenamine silver), consensus by panel raters was reached in 172 of 220 (78%) scenarios, with 103 of 148 (70%) rated “usually appropriate” or “rarely appropriate” and 45 of 148 (30%), “appropriateness uncertain.” Limitations: The study design only measures appropriateness. Cost, availability, test comparison, and additional clinical considerations are not measured. The possibility that the findings of this study may be influenced by the inherent biases of the dermatopathologists involved in the study cannot be excluded.ConclusionsAUC are reported for selected diagnostic tests in clinical scenarios that occur in dermatopathology practice. Adhering to AUC may reduce inappropriate test utilization and improve healthcare delivery.
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression
Investigators, The Parkinson Study Group SURE-PD3, Bluett, Brent , Togasaki, Daniel M., Mihaila, Dragos, Evatt, Marian L., Rezak, Michael, Jain, Samay , Schwarzschild, Michael A. , Ascherio, Alberto, Casaceli, Cindy, Kamp, Cornelia , Lungu, Codrin , Oakes, David , Rudolph, Alice, Shoulson, Ira , Scott, B.L. , Gauger, Lisa, Aldred, Jason , Bixby, Melissa, Ciccarello, Jill, Gunzler, Steven A. , Henchcliffe, Claire , Brodsky, Matthew , Keith, Kellie, Hauser, Robert A. , LeDoux, Mark S. , Hinson, Vanessa K. , Kumar, Rajeev , Hunter, Christine , Christine, Chadwick W. , Daley, Aaron, Leehey, Maureen A. , Marcaida, Joy Antonelle de, Hung, Albert Y. , Bwala, Grace, Simon, David K. , Simuni, Tanya , Poon, Cynthia , Schiess, Mya C. , Park, Ariane , Peterson, Carolyn, Criswell, Susan R. , Durphy, Jennifer, Shill, Holly A. , Mehta, Shyamal H. , Deik, Andres , Fang, John Y., Stover, Natividad , Zhang, Lin , Dewey, Richard B. , Gerald, Ashley, Boyd, James T. , Houston, Emily , Suski, Valerie, Mosovsky, Sherri, Cloud, Leslie , Shah, Binit, James, Raymond , Zauber, S. Elizabeth , Reich, Stephen G. , Langhammer, April, LaFaver, Kathrin , Kaminski, Patricia L. , Goudreau, John L. , Russell, Doozie, Houghton, David , LaRoche, Ashley , Thomas, Karen , McGraw, Martha, Mari, Zoltan, Blindauer, Karen, Rabin, Marcie, Kurlan, Roger, Morgan, John C. , Ainslie, Melissa, Bódis-Wollner, Iván , Waters, Cheryl , Ratel, Amber Servi, Beck, Christopher A. , Bolger, Patrick, Callahan, Katherine F., Crotty, Grace F. , Klements, David , Kostrzebski, Melissa, McMahon, Gearoid M. , Pothier, Lindsay , Hauser, Robert A , Simuni, Tanya , Investigators, The Parkinson Study Group SURE-PD3, Curhan, Gary C. , Fitzgerald, Rebecca, Macklin, Eric A. , Marek, Kenneth , Mozaffarian, Dariush , Videnovic, Aleksandar , Goetz, Christopher G. , Espay, Alberto J. , Jimenez‐Shahed, Joohi , Friedman, Joseph H. , Litvan, Irene , Chou, Kelvin L. , Bhatti, Danish , Rosenthal, Liana S. , Ahmed, Anwar E. , Saint‐Hilaire, Marie , Shprecher, David , Pahwa, Rajesh , LeWitt, Peter A. , Kaminski, Patricia, Thomas, Karen, Serrano, Carmen , Soileau, Michael J , Schneider, Ruth B. , Waikar, Sushrut S. , Lang, Anthony E. , Mestre, Tiago

Mayo Clinic

JAMA | September 14, 2021 | Volume: 326 | Issue: 10 | Pages: 926

10.1001/jama.2021.10207 | PMID 34519802 Get It